Overexpression of the transcription factor E2F-1 induces apoptosis in tumor cells. This apoptotic effect is partly mediated through the induction of the double-stranded RNA-activated protein kinase (PKR). Here, we investigate if agents that upregulate PKR could enhance the apoptotic effect of E2F-1 overexpression in liver tumors. In human hepatocellular carcinoma (HCC) cells (Hep3B, HepG2, Huh7), adenovirus-mediated overexpression of E2F-1 (AdCMV-E2F) transcriptionally increased PKR mRNA. The subsequent increase of total and phosphorylated PKR protein was followed by induction of apoptosis. When AdCMV-E2F was combined with the PKR modifier interferon a (IFNa), PKR was additionally upregulated and both PKR activation and apoptosis were increased. Subcutaneous xenograft tumors were selectively targeted using an adenoviral vector expressing E2F-1 under the control of the human telomerase reverse transcriptase (hTERT) promoter (AdhTERT-E2F). Weekly systemic administration of AdhTERT-E2F inhibited tumor growth. The tumor suppressive effect of AdhTERT-E2F therapy was further enhanced in combination with IFNa.Our results demonstrate that PKR activating agents enhance the anti-tumor effect of E2F-1 overexpression in HCC in-vitro and in-vivo. Hence, modulation of PKR is a potential strategy to increase the efficacy of PKR-dependent anti-tumor therapies.
Introduction
E2F-1 is a member of the E2F family of transcription factors that holds a key role in cell-cycle progression through the G1/S checkpoint, by regulating G1 to S phase transition. 1, 2 Unlike the other members of the E2F family, E2F-1 exhibits a dual role, as it can also selectively induce apoptosis in tumor cells (reviewed in [3] [4] [5] [6] [7] [8] ). We previously showed that E2F-1-induced apoptosis is mediated partly through the activation of the dsRNA-activated protein kinase (PKR). 9 Activation of PKR is a major host defense mechanism against viral infections. Signals produced by viral infection, such as interferon (IFN) or double-stranded RNA induce PKR dimerization, auto-phosphorylation and subsequent activation. 10 A major downstream target of activated PKR is the a subunit of the eukaryotic initiation factor 2 (eIF2a). Phosphorylation of eIF2a impairs protein synthesis at the translation initiation step and results in cell growth arrest and apoptosis. 11, 12 PKR has been found to be downregulated in various tumors. Its low expression correlates with worse prognosis and enhanced tumorigenicity, suggesting that activated PKR has a tumor-suppressor function. 13 Inhibitors of heat-shock protein (HSP)-90 such as 17-allylamino-17-demethoxygeldanamycin (17-AAG) and radicicol have gained recent attention due to their antitumoral function and selective activity in malignant cells. These agents, which are currently being tested in phase I clinical trials, are also activators of PKR. 14, 15 Another PKR modulator, the polyanion heparin, can mimic the effect of double-stranded RNA leading to autophosphorylation and subsequent activation of PKR. 16, 17 The most prominent activator of PKR is IFN. Interferon stimulates IFN response elements and g-activated sequences (GAS) within the PKR promoter. [18] [19] [20] IFN mainly induces the transcriptional increase of PKR mRNA and protein, while other posttranscriptional modifications regulate PKR activity. 21, 22 PKR plays a central role in IFN-based therapies against hepatitis and resistance to IFN is correlated with lower PKR expression. 23 Worldwide, hepatitis B and C infections are the most important etiologic factors in the development of hepatocellular carcinoma (HCC). 24 HCC is the most frequent type of primary liver cancer and has a dire prognosis and low survival probability due, in part, to a lack of efficient anti-tumor therapies.
The purpose of this study was to evaluate if overexpression of E2F-1 induces apoptosis in HCC and if E2F-1 gene therapy inhibits HCC tumor growth. Furthermore, we assessed whether PKR upregulating agents could enhance the effect of E2F-1 overexpression. Ultimately, we tested the combined effect of E2F-1 and PKR upregulation in a mouse xenograft model using an E2F-1 expression vector under control of a tumor-specific promoter (human telomerase reverse transcriptase, hTERT).
Materials and methods
Antibodies and reagents E2F-1 (KH95) and PKR (K-17) antibodies were purchased from SantaCruz Biotechnology (SantaCruz Biotechnology Inc., Heidelberg, Germany), b-actin [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] from Sigma (Sigma, Buchs, Switzerland), phospho-PKR (pT451) from Biosource (Biosource Europe S A, Nivelles, Belgium).
HRP-conjugated secondary antibodies were purchased from DAKO for goat anti-rabbit (Dako, Baar, Switzerland) and Pierce for goat anti-mouse (Perbio Science SA, Lausanne, Switzerland). Interferon a (Roferon-A) and Heparin (Liquemin) were obtained from Roche (Roche Pharma AG, Reinach, Switzerland), Radicicol and 17-allylamino-17-demethoxygeldanamycin (17-AAG) from AG Scientific (AG Scientific Inc., San Diego, CA).
Cell culture
Human hepatocellular carcinoma cell lines Hep3B (p53-deleted), HepG2 (p53-wild type) and Huh7 (p53-mutated) were purchased from ATCC (LCG Promochem, Molsheim, France). All cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heatinactivated fetal calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin (all from Life Technology, Paisley, Scotland) and incubated at 37 1C in a humidified incubator with 5% CO 2 .
Vectors
Replication incompetent adenovirus type 5 with deletions in the region E1/E3 were used to overexpress the transgenes E2F-1 and firefly luciferase under the control of the cytomegalovirus promoter CMV (adenovirusmediated overexpression of E2F-1 (AdCMV-E2F) (from Dr KK Hunt (MD Anderson Cancer Center, Houston); AdCMV-Luc (from Dr Sunil Chada (Introgen Therapeutics, Inc., Houston)). For tumor-selective (telomerasedependent) transgene expression, we constructed a vector in which the human telomerase reverse transcriptase (hTERT) core promoter was used to control E2F-1 expression (AdhTERT-E2F). In previous experiments with a b-Gal expressing adenovirus, we determined that more than 90% of the cells expressed the transgene when they were infected with a multiplicity of infection ( 
Cell viability assay
AlamarBlue (Biosource Europe) is a redox dye that yields a fluorescent signal in response to a metabolic activity. The assay is based on the ability of metabolically active cells to convert the reagent into a fluorescent indicator (emitting at 590 nm). AlamarBlue was diluted in culture medium to a final concentration of 10%. After 2 hours incubation, AlamarBlue reduction was quantified using a Tecan Infinite 200-plate reader set at excitation and emission 544/590 nm respectively. Cell viability was determined as a percentage of AlamarBlue reduction in the treated cells normalized to the reduction in untreated control cells. All combination treatments have been carried out by adding each vector and the agents into the media at the same time. During the treatment the cells media was not changed. Cell viability was assessed in triplets in at least three independent experiments.
FACS
Cells and supernatants were harvested and washed in 1 Â PBS, then resuspended in propidium iodide (PI) solution (50 mg/ml) containing 0.1%Triton X-100, 0.1% sodium citrate and RNAse A (10 mg/ml, Sigma). Cells were analyzed by FACS (Becton Dickinson AG, Basel, Switzerland) for PI incorporation. Sub-G1 phase cell population was determined using FlowJo software (FlowJo, Ashland, OR). FACS analysis was performed with at least three independent experiments.
Mouse model
Experiments were performed according to the National Institute of Health's Guidelines for the Care and Use of Laboratory Animals and with the approval of the local Animal Ethics Committee. 32 Hsd:Athymic Nude-Foxn1 nu mice (male, 4 weeks) were purchased from Harlan (Harlan, Horst, The Netherlands). After 1 week of acclimation, 5 Â 10 5 HepG2 hepatocellular carcinoma cells diluted in 25 ml of medium were injected subcutaneously in the right flank of each mouse. One week after operation, the mice were randomized by 'randomly permutated blocks method' through www.randomization. com and distributed into four groups (PBS, interferon a (IFNa), E2F-1, combination IFNa þ E2F). The following systemic treatment was administrated for a period of 7 weeks: animals received weekly tail-vein injections of AdhTERT-E2F (5 Â 10 8 pfu) diluted in 50 ml PBS (control group received PBS only), and/or 40 000 Units (U) of IFNa in 100 ml PBS intra-peritoneally three times per week (control group received PBS only). Tumor growth was evaluated by measuring the tumor diameters in two dimensions (dim1 and dim2), and mean tumor growth per day was calculated with the formula (
))/ days treatment (start to end ( ¼ 49 days)). For direct intratumoral treatment, 20 ml AdCMV-E2F (1 Â 10 7 pfu) or PBS was injected into subcutaneous tumors. This intratumoral treatment was initiated at a mean tumor diameter of 5 mm and continued over a period of 17 days. The human hepatocellular xenografts were harvested and fixed in formalin 4% for 24 h, then incubated in ethanol 70% for another 48 h before embedding in paraffin for immunohistochemistry.
Immunohistochemistry Paraffin-embedded samples were cut into 5 mm-thin sections for analysis. Deparaffinized sections were microwave-heated for 20 min in 0.01 M Na-citrate, pH 6.4, for antigen retrieval. Endogenous peroxidases were blocked by 0.3% H 2 O 2 in methanol for 30 min. Sections were incubated with PKR (K-17) antibody (1/100) overnight at 4 1C. Samples were washed in PBS before incubation with the secondary antibody (biotinylated goat anti-rabbit 1/200, Vectastains (Vector Laboratories Inc., Burlingame, CA)) for 1 h. Sections were further developed with components of the Vectastains Kit (Vector Laboratories Inc.) according to the manufacturer's instructions. Immunoreactivity was developed using 3,3 0 -diaminobenzidine (Sigma Fast) as the peroxidase substrate and nuclei were counterstained with hematoxylin.
Statistical analysis
Mann-Whitney rank sum tests were performed to assess the significance of all differences observed in the in-vitro cell viability assays. The significance of the differences between two treatment groups in the in-vivo study was determined with the students t-test and difference over all groups was determined by ANOVA. P-values below 0.05 were considered to be statistically significant. All in vitro experiments were performed at least three independent times.
Results

E2F-1 up-regulates PKR and induces apoptosis in HCC cell lines
To investigate the effect of E2F-1 overexpression in HCC, HCC cell lines were treated with two adenoviral vectors, AdCMV-E2F or AdhTERT-E2F. Cell viability assays demonstrated that overexpression of E2F-1 had a cytotoxic effect in HCC cell lines. 72 h after infection with AdCMV-E2F, the viability of Hep3B, HepG2 and Huh7 cells was reduced to 36, 66 and 33%, respectively, compared to uninfected cells (Figure 1a ). When infected with an adenovirus expressing E2F-1 under the control of a tumor-specific, telomerase-dependent promoter (Adh-TERT-E2F), the cytotoxic effect was less pronounced, as cell viability was reduced to only 48% (Hep3B), 87% (HepG2) and 84% (Huh7) of the control cells (Figure 1a) .
Quantification of propidium iodide incorporation by FACS analysis demonstrated that the sub-G1 cell population increased after E2F-1 overexpression, indicating that cell-death occurred by apoptosis (Figure 1b) . In all cell lines, adenovirus-mediated E2F-1 overexpression resulted in a 5-to 10-fold increase of the sub-G1 population. Apoptosis was apparent after 48 h of infection in Hep3B and Huh-7 cells (Figure 1b) ; however, in HepG2 cells apoptosis was delayed, becoming apparent after 72 h. Further analysis revealed that infection of HCC cells with AdCMV-E2F upregulated PKR protein PKR modulation enhances E2F-1 gene therapy in HCC V Roh et al (Figure 1c) . Real time PCR analysis confirmed that the increase of PKR protein was due to the increased levels of PKR mRNA (Figure 1d) . Treatment with the control luciferase-expressing vector (AdCMV-Luc) did not increase PKR expression. Hence, PKR upregulation was specific to E2F-1 overexpression and independent of the adenoviral vector backbone. PKR protein increased after 24 h in Hep3B and Huh-7 cells (Figure 1c) . Consistent with the delay of apoptosis observed in HepG2 cells (Figure 1b) , PKR upregulation was also delayed in this cell line, becoming apparent only after 48 h (Figure 1c) .
These results show that E2F-1 overexpression in HCC cells result in decreased cell viability due to apoptosis, which is associated with upregulation of PKR, both at protein and at mRNA levels.
PKR-activating agents show a time-and dose-dependent toxicity in HCC cells
Interferon a, heparin and the heat-shock protein 90 inhibitors, 17-AAG and radicicol modify PKR activity. 20, 17, 25, 14 To determine their effect on HCC cells, viability assays were performed in the Hep3B cell line. Concentrations were chosen based on previously reported studies. [25] [26] [27] [28] [29] Increasing concentrations of the PKR modifiers radicicol, heparin and 17-AAG reduced cell viability in a time and dose-dependent manner (Figures  2a-c) , whereas IFNa showed no cytotoxic effect (Figure 2d ).
Combination of E2F-1 overexpression with radicicol or IFNa enhances cytotoxicity in Hep3B cells
We next questioned whether the combination of PKRmodifying agents with E2F-1 overexpression would lead to an enhanced cytotoxic effect in HCC cells. To answer this, the viability of Hep3B cells was measured after treatment with the PKR modifiers radicicol or IFNa, either alone or in combination with E2F-1 overexpression. Treatment with radicicol (0.05 mM) alone resulted in 51% cytotoxicity compared to untreated cells. Overexpressing E2F-1 by AdCMV-E2F or AdhTERT-E2F resulted in a cytotoxicity of 64 and 48%, respectively, which was significantly increased to 75 and 62% when combined with radicicol (Po0.03) (Figure 3a) . Likewise, combining AdCMV-E2F or AdhTERT-E2F with IFNa (1000 U/ml) significantly increased cytotoxicity to 72 and 55%, respectively (Po0.03) (Figure 3b) . The increased cytotoxicity obtained by combination with radicicol or IFNa was specific to E2F-1 overexpression and independent of the adenoviral vector backbone, because in cells infected with the luciferase expressing vector (AdCMV-Luc) cytoxicity was not increased. IFNa as a single-agent or in combination with AdCMV-Luc had no significant toxicity; however, IFNa strongly enhanced the cytotoxic effect of E2F-1 overexpression. Taken together, the combination of PKR modifiers with E2F-1 overexpression leads to enhanced cytotoxicity in Hep3B cells.
Increased apoptosis by combination of E2F-1 overexpression with IFNa correlates with higher PKR mRNA and protein levels, as well as enhanced PKR activation
We next wanted to demonstrate that the enhanced cytotoxic effect of E2F-1 and IFNa is correlated with increased apoptosis and PKR activation. Consistent with its cytotoxic effect on Hep3B cells, E2F-1 overexpression IFNa alone or in combination with AdCMV-Luc had no apoptotic effect. Coherent with its induced apoptosis, E2F-1 overexpression increased both PKR and phospho-PKR protein levels (Figure 3c, western blot) . PKR upregulation and PKR activation were further amplified, when E2F-1 overexpression was combined with IFNa. IFNa treatment alone also increased both total and phosphorylated PKR protein; however, at lower levels than after E2F-1 treatment. Therefore, interestingly, IFNa alone did not induce apoptosis despite upregulated PKR protein levels.
PKR protein levels were reflected by PKR mRNA levels after treatment with AdCMV-E2F or IFNa alone or in combination (Figure 3d ). When cells were treated with IFNa alone or in combination with AdCMV-Luc, PKR mRNA increased fivefold compared to the PBS control level. The combination of IFNa with AdCMV-E2F resulted in a 27-fold increase of PKR mRNA (Figure 3d) .
Hence, we demonstrate that PKR mRNA, PKR protein and activated PKR relate with the extent of apoptosis and cytotoxicity after AdCMV-E2F treatment alone or in combination with IFNa. PKR modulation enhances E2F-1 gene therapy in HCC V Roh et al Suppression of HCC tumors by E2F-1 gene therapy is enhanced by the combination with IFNa Next, we studied the anti-tumoral effect of EF2-1 overexpression alone and in combination with IFNa in vivo. Preliminary experiments established HepG2 cells as a standard for our HCC tumor xenograft model, because they efficiently develop into subcutaneous tumors when injected into the flank of immunodeficient mice. Therefore, we injected HepG2 cells into nude mice, and the following treatments were initiated 7 days after tumor cell injection and continued for 7 weeks: PBS, IFNa, AdhTERT-E2F or a combination of IFNa and AdhTERT-E2F. Tumor sizes were monitored by measuring the tumor diameters in two dimensions, and mean tumor growth per day was calculated.
Tumors in animals treated with AdhTERT-E2F showed a trend to slower progression (Figure 4a ) and smaller tumors at the end of the experiments than in control-treated animals. However, the large variance in tumor growth in the PBS control group did not allow it to reach statistical significance levels. In contrast, treatment with AdhTERT-E2F alone or in combination with IFNa showed a significant suppressive effect on HCC tumor growth compared to IFNa treatment alone (P ¼ 0.02). Moreover, these results indicate that the combination therapy was the most effective anti-tumor treatment.
During the course of the experiment no acute or chronic toxicity was observed. This is consistent with previous experiments where systemic AdhTERT-E2F application at doses up to 5 Â 10 9 plaque forming units (pfu) per week was not toxic to the liver (no elevation of liver enzymes) (data not shown).
Combination of adenovirus mediated E2F-1 overexpression with IFNa increases PKR expression in HCC tumors
We used the same subcutaneous xenografted HepG2 tumor model to study PKR expression in tumor tissue. Mice received either PBS or IFNa by intraperitoneal injection and, additionally, AdCMV-E2F or PBS intratumorally. PKR expression in the xenograft tumors was then evaluated by immunohistochemistry. Whereas, PKR was expressed at very low levels in tumors treated with PBS, both IFNa and AdCMV-E2F treatment resulted in increased staining for PKR expression. The combination of intratumoral AdCMV-E2F with systemic IFNa further increased PKR expression in the tumors compared to single-agent treatment (Figure 4b ).
Discussion
We showed that adenovirus-mediated overexpression of the transcription factor E2F-1 induces cytotoxicity, PKR upregulation and apoptosis in hepatocellular carcinoma in vitro and in vivo. The less pronounced cytotoxic effect of AdhTERT-E2F compared to AdCMV-E2F can be explained by the weaker transgene expression from the hTERT promoter (10-50% of transgene expression levels reached from the unspecific CMV promoter (data not shown)). In HepG2 cells, a delay in PKR upregulation and induction of apoptosis was observed. This is consistent with studies which showed HepG2 cells to be less sensitive to cytotoxic treatments compared to Hep3B cells (probably due to active p53). 30, 31 We studied various PKR-inducing agents that showed dose-dependent cytotoxicity in HCC cells. The combination of E2F-1 overexpression with the PKR-inducing agents radicicol and IFNa resulted in a strong increase of PKR modulation enhances E2F-1 gene therapy in HCC V Roh et al cytotoxicity. Although IFNa treatment alone resulted in PKR upregulation and activation (at low levels), no cytotoxicity of IFNa was observed in our experiments. The low cytotoxicity of IFNa is consistent with the existing literature 27 and suggests that PKR upregulation alone is not sufficient to induce apoptosis. However, combination of E2F-1 overexpression with IFNa resulted in a synergistic effect on PKR activation and enhanced apoptosis in HCC cell lines. The in vivo experiments with a tumor-specific expression vector further confirmed this enhanced anti-tumor effect of E2F-1 gene therapy in combination with IFNa. Like in our in vitro experiments, increased PKR expression in tumors reflected the enhanced effect of E2F-1 with IFNa on HCC growth suppression.
Our findings corroborate the described pro-apoptotic effect of E2F-1 overexpression in various other cell lines and tumors. Previously, we reported that this proapoptotic effect is, at least partly, mediated by PKR. 9 Here, we show that additionally increasing PKR expression and activation by PKR-modifying agents lead to increased cytotoxicity of E2F-1 overexpression on HCC in vitro and in vivo. Noticeably, these effects were not due to interference with the viral vector backbone as combination with a luciferase expressing adenovirus did not result in PKR upregulation or additional cytotoxicity. These findings correlate with an in vitro work by Pataer et al. 32 showing that treatment of lung cancer cell lines with melanoma differentiation antigen 7 (mda-7) was more efficient in combination with PKR modifiers.
The principle to re-establish, overexpress and activate PKR in tumors is attractive because PKR downregulation per se seems to increase tumorigenicity in cancers. 13 In those PKR downregulated tumors, which are often virally induced (like in HCC), the virus-mediated PKR inhibition could be counteracted by the therapeutic effect of E2F-1 in combination with PKR modifiers. 33 Our findings demonstrate, that PKR modification by agents, that are clinically already in use, is an attractive and effective strategy to enhance E2F-1 gene therapy against cancer. The novelty of this work is that modulating PKR can be used to increase anti-tumor efficiency of PKR-dependent gene therapies.
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